943TiP PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
Year: 2023
Type: article
Source: Annals of Oncology
Authors: N. Saba, H. Youssoufian, E. Cohen, J. Singh, L. Makris, M. Perdomini, S. MacIntyre, A. Denker
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4387811161